Masoud Keikha
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
Masoud Keikha has a total of 94 co-authors. Here are the top co-authors by number of shared publications:
- Mohsen Karbalaei
Department of Microbiology and Virology, School of Medicine Jiroft University of Medical Sciences Jiroft Iran
25 shared publications Kiarash Ghazvini
Department of Microbiology and Virology, Faculty of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran
24 shared publicationsMohsen Karbalaei
Department of Microbiology and Virology, School of Medicine, Jiroft University of Medical Sciences, Jiroft, Iran
21 shared publications- Kiarash Ghazvini
Department of Microbiology and Virology, School of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran
9 shared publications Masoud Youssefi
Antimicrobial Resistance Research Center, Mashhad University of Medical Sciences, Mashhad, Iran; Department of Microbiology and Virology, Faculty of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran
9 shared publicationsAli Beheshti Namdar
7 shared publications
Latest Publications
- 11 March 2026
- Published by Elsevier in Translational Research
- Vol. 290, 61-81
Harnessing innate lymphoid cells (ILCs) for cancer immunotherapy: A new frontier in precision immuno-oncology
- 11 March 2026
- Published by Elsevier in Translational Research
- Vol. 290, 61-81
Harnessing innate lymphoid cells (ILCs) for cancer immunotherapy: A new frontier in precision immuno-oncology
- 22 December 2025
- Published by Springer Nature in Molecular Diversity
- Vol. 30 (4) , 4759-4814
Exploration of the protein and pharmacological landscape of monkeypox virus treatment: from entry point to end point
The re-emergence of monkeypox virus (MPXV), renamed mpox, as a global health emergency in 2022 has intensified the search for robust therapeutic interventions. This review summarizes the virological, structural, and pharmacological dimensions of MPXV, with a focus on the virus's lifecycle from host cell entry to dissemination. MPXV’s double-stranded DNA genome exhibits clade-specific plasticity, with variations in genes like OPG065 and MOPICE driving virulence, immune evasion, and host adaptation. Key viral proteins, including entry facilitators A27L and L1R, envelope protein F13L (VP37), and immune modulators such as B19R and C12L, serve as critical targets for antiviral strategies. Structural insights from cryo-EM and X-ray crystallography reveal conserved motifs across orthopoxviruses, enabling pan-orthopox drug design. Current therapeutics, such as tecovirimat (targeting VP37 to block egress), brincidofovir, and cidofovir (inhibiting DNA polymerase E9L), offer symptomatic relief but face hurdles like resistance mutations (e.g., A314V in E9L) and suboptimal efficacy in immunocompromised patients. Emerging resistance underscores the need for vigilant genomic surveillance. Novel modalities, including monoclonal antibodies against antigenic proteins like A35R and M1R, cytokine-based immunotherapies, and host-directed agents modulating autophagy or interferon pathways, show promise. Computational approaches integrating AI-driven screening, molecular dynamics simulations, and multi-omics have pinpointed repurposed candidates like lumacaftor and conivaptan as VP37 inhibitors. This integrative framework advocates for combination therapies, personalized regimens based on clade profiling, and global collaboration to mitigate MPXV's adaptive potential. By bridging virology and pharmacology, the review charts pathways for innovative drug development to combat this zoonotic threat effectively.
- 22 December 2025
- Published by Springer Nature in Molecular Diversity
- Vol. 30 (4) , 4759-4814
Exploration of the protein and pharmacological landscape of monkeypox virus treatment: from entry point to end point
The re-emergence of monkeypox virus (MPXV), renamed mpox, as a global health emergency in 2022 has intensified the search for robust therapeutic interventions. This review summarizes the virological, structural, and pharmacological dimensions of MPXV, with a focus on the virus's lifecycle from host cell entry to dissemination. MPXV’s double-stranded DNA genome exhibits clade-specific plasticity, with variations in genes like OPG065 and MOPICE driving virulence, immune evasion, and host adaptation. Key viral proteins, including entry facilitators A27L and L1R, envelope protein F13L (VP37), and immune modulators such as B19R and C12L, serve as critical targets for antiviral strategies. Structural insights from cryo-EM and X-ray crystallography reveal conserved motifs across orthopoxviruses, enabling pan-orthopox drug design. Current therapeutics, such as tecovirimat (targeting VP37 to block egress), brincidofovir, and cidofovir (inhibiting DNA polymerase E9L), offer symptomatic relief but face hurdles like resistance mutations (e.g., A314V in E9L) and suboptimal efficacy in immunocompromised patients. Emerging resistance underscores the need for vigilant genomic surveillance. Novel modalities, including monoclonal antibodies against antigenic proteins like A35R and M1R, cytokine-based immunotherapies, and host-directed agents modulating autophagy or interferon pathways, show promise. Computational approaches integrating AI-driven screening, molecular dynamics simulations, and multi-omics have pinpointed repurposed candidates like lumacaftor and conivaptan as VP37 inhibitors. This integrative framework advocates for combination therapies, personalized regimens based on clade profiling, and global collaboration to mitigate MPXV's adaptive potential. By bridging virology and pharmacology, the review charts pathways for innovative drug development to combat this zoonotic threat effectively.
- Open Access
- 6 December 2025
- Published by Springer Nature in BMC Infectious Diseases
- Vol. 26 (1)
Empirical therapy versus tailored therapy for Helicobacter pylori infection? A systematic review
The global decline in the efficacy of empirical treatment for Helicobacter pylori eradication driven largely by rising antibiotic resistance has prompted i
- 6 December 2025
- Published by Springer Nature in BMC Infectious Diseases
- Vol. 26 (1)
Open AccessEmpirical therapy versus tailored therapy for Helicobacter pylori infection? A systematic review
The global decline in the efficacy of empirical treatment for Helicobacter pylori eradication driven largely by rising antibiotic resistance has prompted i
- Open Access
- 21 October 2025
- Published by Springer Nature in BMC Infectious Diseases
- Vol. 25 (1) , 1-9
Severe Multi-organ dysfunction secondary to Shigella flexneri encephalopathy (Ekiri Syndrome): a case report and review of the literature
Shigella infection is a major global cause of diarrhea, particularly among children in low- and middle-income countries. While most cases are self-limited, certain strains such as Shigella flexneri can lead to severe systemic complications, including encephalopathy. Among the rarest and most fatal forms is Ekiri syndrome, primarily reported in East Asian literature, characterized by fulminant neurotoxicity, high fever, seizures, and rapid progression to coma or death. In this study, we report the case of a previously healthy 14-year-old girl who presented with vomiting, diarrhea, and low-grade fever, initially treated conservatively. Her condition worsened with progressive lethargy and a generalized seizure, leading to ICU admission. Brain imaging showed diffuse cerebral edema, and her temperature intermittently spiked to 44–45 °C. Laboratory findings revealed marked leukopenia, and stool culture confirmed Shigella flexneri. Despite supportive management including anticonvulsants, empiric antibiotics, and antivirals for suspected CNS infection, her neurologic status continued to deteriorate. As per family request, she was referred to a tertiary center, where her condition rapidly worsened. She developed multi-organ failure with acute kidney injury requiring dialysis, elevated liver enzymes, cardiac dysfunction, and pneumothorax. Despite intensive care, she succumbed to complications after nearly ten days of hospitalization. This case illustrates a fulminant presentation of Shigella-associated encephalopathy consistent with Ekiri syndrome. Clinicians should maintain a high index of suspicion in pediatric patients with gastrointestinal and early neurological symptoms. Early recognition and aggressive supportive care are essential to improving outcomes in this rare but devastating condition.
- 21 October 2025
- Published by Springer Nature in BMC Infectious Diseases
- Vol. 25 (1) , 1-9
Open AccessSevere Multi-organ dysfunction secondary to Shigella flexneri encephalopathy (Ekiri Syndrome): a case report and review of the literature
Shigella infection is a major global cause of diarrhea, particularly among children in low- and middle-income countries. While most cases are self-limited, certain strains such as Shigella flexneri can lead to severe systemic complications, including encephalopathy. Among the rarest and most fatal forms is Ekiri syndrome, primarily reported in East Asian literature, characterized by fulminant neurotoxicity, high fever, seizures, and rapid progression to coma or death. In this study, we report the case of a previously healthy 14-year-old girl who presented with vomiting, diarrhea, and low-grade fever, initially treated conservatively. Her condition worsened with progressive lethargy and a generalized seizure, leading to ICU admission. Brain imaging showed diffuse cerebral edema, and her temperature intermittently spiked to 44–45 °C. Laboratory findings revealed marked leukopenia, and stool culture confirmed Shigella flexneri. Despite supportive management including anticonvulsants, empiric antibiotics, and antivirals for suspected CNS infection, her neurologic status continued to deteriorate. As per family request, she was referred to a tertiary center, where her condition rapidly worsened. She developed multi-organ failure with acute kidney injury requiring dialysis, elevated liver enzymes, cardiac dysfunction, and pneumothorax. Despite intensive care, she succumbed to complications after nearly ten days of hospitalization. This case illustrates a fulminant presentation of Shigella-associated encephalopathy consistent with Ekiri syndrome. Clinicians should maintain a high index of suspicion in pediatric patients with gastrointestinal and early neurological symptoms. Early recognition and aggressive supportive care are essential to improving outcomes in this rare but devastating condition.
- 23 September 2025
- Published by Elsevier in Arab Journal of Gastroenterology
- Vol. 26 (4) , 320-321
Comments on “Clinical features and temporal trends in H. pylori negative gastric maltoma”
- 23 September 2025
- Published by Elsevier in Arab Journal of Gastroenterology
- Vol. 26 (4) , 320-321
Comments on “Clinical features and temporal trends in H. pylori negative gastric maltoma”
- Open Access
- 14 September 2025
- Published by Wiley in Health Science Reports
- Vol. 8 (9)
Global Profile of Drug Resistance Related to Helicobacter pylori Infection in Children: A Systematic Review and Meta‐Analysis
Background and Aims: The increasing prevalence of antibiotic‐resistant Helicobacter pylori ( H. pylori ) strains represents a critical impediment to successful eradication therapy in both pediatric and adult populations. This meta‐analysis aimed to determine the current global landscape of primary antibiotic resistance in bacterial isolates obtained from children. Methods: A systematic literature search was conducted across ISI Web of Science, PubMed, Scopus, and Google Scholar, encompassing the period from the inception of each database up to December 2021. Eligible studies reporting primary antibiotic resistance in H. pylori isolates from children worldwide were included. Resistance rates were expressed as percentages with corresponding 95% confidence intervals. Statistical analysis was performed using Comprehensive Meta‐Analysis 2.2. Results: One hundred eleven teens were included in this meta‐analysis, and 36,021 isolates of this bacterium were evaluated. The resistance rate was reported 25.6%, 30.9%, 2.5%, 2.0%, 12.1%, 6.9%, 1.9%, 0.5%, and 9.1%, for clarithromycin, metronidazole, amoxicillin, tetracycline, levofloxacin, ciprofloxacin, furazolidone, nitrofurantoin, and rifampin respectively. Furthermore, the pooled prevalence of primary multidrug resistant isolates was 4.5%. Conclusion: This meta‐analysis reveals a significant global burden of primary resistance to clarithromycin and metronidazole in pediatric H. pylori isolates, with evidence of increasing resistance over time. Conversely, resistance rates to amoxicillin, tetracycline, levofloxacin, ciprofloxacin, furazolidone, nitrofurantoin, and rifampin remained low. Consequently, therapeutic regimens incorporating clarithromycin and metronidazole should be carefully considered and potentially avoided in regions exhibiting resistance rates exceeding 20%.
- 14 September 2025
- Published by Wiley in Health Science Reports
- Vol. 8 (9)
Open AccessGlobal Profile of Drug Resistance Related to Helicobacter pylori Infection in Children: A Systematic Review and Meta‐Analysis
Background and Aims: The increasing prevalence of antibiotic‐resistant Helicobacter pylori ( H. pylori ) strains represents a critical impediment to successful eradication therapy in both pediatric and adult populations. This meta‐analysis aimed to determine the current global landscape of primary antibiotic resistance in bacterial isolates obtained from children. Methods: A systematic literature search was conducted across ISI Web of Science, PubMed, Scopus, and Google Scholar, encompassing the period from the inception of each database up to December 2021. Eligible studies reporting primary antibiotic resistance in H. pylori isolates from children worldwide were included. Resistance rates were expressed as percentages with corresponding 95% confidence intervals. Statistical analysis was performed using Comprehensive Meta‐Analysis 2.2. Results: One hundred eleven teens were included in this meta‐analysis, and 36,021 isolates of this bacterium were evaluated. The resistance rate was reported 25.6%, 30.9%, 2.5%, 2.0%, 12.1%, 6.9%, 1.9%, 0.5%, and 9.1%, for clarithromycin, metronidazole, amoxicillin, tetracycline, levofloxacin, ciprofloxacin, furazolidone, nitrofurantoin, and rifampin respectively. Furthermore, the pooled prevalence of primary multidrug resistant isolates was 4.5%. Conclusion: This meta‐analysis reveals a significant global burden of primary resistance to clarithromycin and metronidazole in pediatric H. pylori isolates, with evidence of increasing resistance over time. Conversely, resistance rates to amoxicillin, tetracycline, levofloxacin, ciprofloxacin, furazolidone, nitrofurantoin, and rifampin remained low. Consequently, therapeutic regimens incorporating clarithromycin and metronidazole should be carefully considered and potentially avoided in regions exhibiting resistance rates exceeding 20%.
- Open Access
- 1 July 2025
- Published by Maad Rayan Publishing Company in International Journal of Infectious Diseases
- Vol. 28 (7) , 423-424
Reevaluating Authorship in the Age of AI: The Case Against ChatGPT as a Scientific Co-Author
Reevaluating Authorship in the Age of AI: The Case Against ChatGPT as a Scientific Co-Author
- 1 July 2025
- Published by Maad Rayan Publishing Company in International Journal of Infectious Diseases
- Vol. 28 (7) , 423-424
Open AccessReevaluating Authorship in the Age of AI: The Case Against ChatGPT as a Scientific Co-Author
Reevaluating Authorship in the Age of AI: The Case Against ChatGPT as a Scientific Co-Author
- Open Access
- 18 June 2025
- Published by Elsevier in New Microbes and New Infections
- Vol. 66
Comments on “A case of Flavobacterium lindanitolerans meningitis and bacteraemia in an immunocompetent host”
- 18 June 2025
- Published by Elsevier in New Microbes and New Infections
- Vol. 66
Open AccessComments on “A case of Flavobacterium lindanitolerans meningitis and bacteraemia in an immunocompetent host”